Second, further functional studies are required to confirm the role of the nucleotide synthesis pathway in ROS1+ NSCLC, its targeting might enhance the sensitivity towards checkpoint inhibitors as reported by Wu et al. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.